Generali Asset Management SPA SGR Sells 939 Shares of United Therapeutics Corporation $UTHR

Generali Asset Management SPA SGR lowered its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 89.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 109 shares of the biotechnology company’s stock after selling 939 shares during the quarter. Generali Asset Management SPA SGR’s holdings in United Therapeutics were worth $59,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of UTHR. Toth Financial Advisory Corp lifted its stake in United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 48 shares in the last quarter. Fiduciary Financial Advisors acquired a new position in shares of United Therapeutics in the second quarter worth about $30,000. Caitlin John LLC purchased a new position in shares of United Therapeutics in the second quarter worth approximately $37,000. International Assets Investment Management LLC increased its position in shares of United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 64 shares in the last quarter. Finally, PFS Partners LLC purchased a new position in shares of United Therapeutics in the third quarter worth approximately $45,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In related news, EVP Paul Mahon sold 8,300 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $544.30, for a total transaction of $4,517,690.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at approximately $24,587,119.60. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $585.49, for a total transaction of $5,562,155.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $189,958,132.07. This represents a 2.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 401,528 shares of company stock valued at $210,097,491 over the last three months. 8.60% of the stock is owned by insiders.

United Therapeutics Trading Up 0.9%

Shares of United Therapeutics stock opened at $598.72 on Friday. United Therapeutics Corporation has a 1 year low of $430.02 and a 1 year high of $609.99. The company has a market cap of $25.68 billion, a P/E ratio of 21.42, a P/E/G ratio of 4.30 and a beta of 0.49. The stock has a 50-day moving average price of $527.10 and a 200 day moving average price of $530.54.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The company had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the previous year, the business posted $6.41 EPS. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. On average, equities analysts forecast that United Therapeutics Corporation will post 26.09 earnings per share for the current fiscal year.

United Therapeutics declared that its board has approved a stock repurchase plan on Thursday, October 22nd that authorizes the company to buy back $2 billion in shares. This buyback authorization authorizes the biotechnology company to reacquire up to 8.3% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Bank of America cut their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Leerink Partners raised their price objective on shares of United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a research note on Monday, October 19th. UBS Group set a $725.00 price objective on shares of United Therapeutics in a research report on Monday, October 19th. Raymond James Financial reissued an “outperform” rating and set a $717.00 target price on shares of United Therapeutics in a research note on Tuesday, October 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $850.00 target price on shares of United Therapeutics in a research note on Monday. Twelve analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $667.07.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.